Drugs / DTaP-IPV-HB-Hib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03205371 | Nov 2016 → Jul 2018 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV-HB-Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03205371 ↗ |
| Modality | Vaccine | “Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed)” NCT03205371 ↗ |